Aurora Cannabis (ACB) Depreciation & Amortization (CF) (2017 - 2025)
Aurora Cannabis (ACB) posted quarterly Depreciation & Amortization (CF) of $1.4 million for Q1 2025, down 75.28% year-on-year from $5.6 million in Q1 2024, and down 63.49% on a QoQ basis from $3.8 million in Q4 2024.
Aurora Cannabis (ACB) Depreciation & Amortization (CF) (2017 - 2025) Analysis & Trends
Aurora Cannabis (ACB) has reported Depreciation & Amortization (CF) for 9 consecutive years, with $1.4 million the latest figure, recorded in Q1 2025.
- Quarterly Depreciation & Amortization (CF) fell 75.28% year-over-year to $1.4 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (down 91.99% YoY) and the FY2026 annual result came in at $9.7 million, down 25.62% from the prior year.
- Depreciation & Amortization (CF) fell to $1.4 million in Q1 2025 per ACB's latest filing, from $3.8 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for ACB reached as high as $24.6 million in Q4 2022 and fell as low as $1.4 million in Q1 2025.
- A 5-year average of $9.6 million and a median of $5.7 million in 2021 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 87.03% — and 2023, when it tumbled 77.75%.
- Year by year, Depreciation & Amortization (CF) stood at $14.0 million in 2021, then soared by 76.3% to $24.6 million in 2022, then slumped by 77.75% to $5.5 million in 2023, then slumped by 30.7% to $3.8 million in 2024, then sank by 63.49% to $1.4 million in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1.4 million, $3.8 million, and $3.8 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Aurora Cannabis | 1.11 Bn | 1.03 Bn | 21.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.39 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | 3.80 Mn |
| Dec 31, 2024 | 3.80 Mn |
| Sep 30, 2024 | 3.79 Mn |
| Sep 30, 2024 | 3.79 Mn |
| Jun 30, 2024 | 4.12 Mn |
| Jun 30, 2024 | 4.12 Mn |
| Mar 31, 2024 | 5.61 Mn |
| Mar 31, 2024 | 5.61 Mn |
| Dec 31, 2023 | 5.48 Mn |
| Dec 31, 2023 | 5.48 Mn |
| Sep 30, 2023 | 5.41 Mn |
| Sep 30, 2023 | 5.41 Mn |
| Dec 31, 2022 | 24.64 Mn |
| Dec 31, 2022 | 24.64 Mn |
| Sep 30, 2022 | 16.85 Mn |
| Sep 30, 2022 | 16.85 Mn |
| Jun 30, 2022 | 9.91 Mn |
| Jun 30, 2022 | 9.91 Mn |